New imaging agents could spot rare brain disease earlier
NCT ID NCT07348276
First seen Jan 17, 2026 · Last updated Jun 09, 2026 · Updated 17 times
Summary
This study tests two new imaging drugs, [18F]ABBV-964i and [18F]ABBV-965i, used with PET scans to see tau protein buildup in the brain, which is linked to Progressive Supranuclear Palsy (PSP). The main goals are to check safety and how well these drugs show tau in the brain. About 24 adults (healthy or with PSP) will join this early-phase trial to help develop better tools for diagnosing and tracking PSP.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Invicro (dba Perceptive)
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.